Table 2 Distribution of the studied cases according to pulmonary complications
From: Evaluation of pulmonary complications in patients undergoing allogenic stem cell transplantation
| Â | No. (%) |
|---|---|
Method to obtain sample(n = 10) | |
 Induced sputum | 6 (60.0) |
 F.O.B | 2 (20.0) |
 Sputum | 1 (10.0) |
 MiniBAL | 1 (10.0) |
Bacterial culture (n = 10) | |
 Negative | 8 (80.0) |
 Streptococcus pneumoniae | 1 (10.0) |
 Klebsiella with multidrug resistant | 1 (10.0) |
CMV sputum (n = 10) | |
 Negative | 9 (90.0) |
 Weak positive | 1 (10.0) |
AFB smear (n = 10) | |
 Negative | 10 (100.0) |
Fungal culture (n = 10) | |
 Negative | 7 (70.0) |
 Candida | 3 (30.0) |
PJP (n = 10) | |
 Negative | 10 (90.0) |
CMV serum (n = 20) | |
 Negative | 14 (70%) |
 Positive | 6 (30%) |
CMV reactivation (n = 19)* | |
 No | 16 (84.2%) |
 Yes | 3 (15.8%) |
Infectious pulmonary complications(n = 10) | |
 No | 5 (50%) |
 Yes | 5 (50%) |
Noninfectious pulmonary complications (n = 20) | |
 No | 19 (95%) |
 Yes | 1 (5%) |